SCHEMBL9952189

SCHEMBL9952189

CCCC(=O)c1ccc(C(=O)NCCC(=O)OC)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.53
MAPT P10636 4/20 0.53
PRSS1 P07477 1/20 0.51
CTSG P08311 1/20 0.51
CTRB1 P17538 1/20 0.51
CMA1 P23946 1/20 0.51
THRA P10827 1/20 0.51
THRB P10828 1/20 0.51
ALDH1A1 P00352 2/20 0.50
HSD17B3 P37058 1/20 0.50
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
HPGD P15428 3/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
LMNA P02545 1/20 0.46
HTT P42858 1/20 0.46
KMT2A Q03164 2/20 0.44
STS P08842 1/20 0.44
KDM4E B2RXH2 1/20 0.44
POLB P06746 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2653898 0.90 THRA (0.58) SMN1; SMN2MAPTPRSS1CTSGCTRB1
SCHEMBL14551257 0.83 PLK1 (0.57) SMN1; SMN2MAPTPRSS1CTSGCTRB1
SCHEMBL14120823 0.82 POLB (0.62) SMN1; SMN2MAPTPRSS1CTSGCTRB1
SCHEMBL2273935 0.82 PRSS1 (0.56) SMN1; SMN2MAPTPRSS1CTSGCTRB1
SCHEMBL11901025 0.82 PRSS1 (0.49) SMN1; SMN2MAPTPRSS1CTSGCTRB1
SCHEMBL2667533 0.81 LMNA (0.56) SMN1; SMN2MAPTPRSS1CTSGCTRB1
SCHEMBL27335124 0.81 PRSS1 (0.54) SMN1; SMN2MAPTPRSS1CTSGCTRB1
SCHEMBL5012300 0.80 PRSS1 (0.77) SMN1; SMN2PRSS1CTSGCTRB1CMA1
SCHEMBL2402293 0.80 PLK1 (0.53) SMN1; SMN2MAPTPRSS1CTSGCTRB1
SCHEMBL27941667 0.80 MAPT (0.61) SMN1; SMN2MAPTPRSS1CTSGCTRB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160362392-A1 GLUCAGON RECEPTOR MODULATORS PFIZER INC. (US) 2016-12-15 US disclosed
US-20160362392-A1 GLUCAGON RECEPTOR MODULATORS PFIZER INC. (US) 2016-12-15 US disclosed
US-20160362392-A1 GLUCAGON RECEPTOR MODULATORS PFIZER INC. (US) 2016-12-15 US disclosed
US-9452999-B2 Glucagon receptor modulators PFIZER INC. (US) 2016-09-27 US disclosed
US-9452999-B2 Glucagon receptor modulators PFIZER INC. (US) 2016-09-27 US disclosed
US-9452999-B2 Glucagon receptor modulators PFIZER INC. (US) 2016-09-27 US disclosed
EP-2673260-B1 GLUCAGON RECEPTOR MODULATOR PFIZER (US) 2016-08-17 EP disclosed
EP-2673260-B1 GLUCAGON RECEPTOR MODULATOR PFIZER (US) 2016-08-17 EP disclosed
US-20150266859-A1 GLUCAGON RECEPTOR MODULATORS PFIZER INC. (US) 2015-09-24 US disclosed
US-20150266861-A1 Glucagon Receptor Modulators PFIZER INC. (US) 2015-09-24 US disclosed
US-8507533-B2 Glucagon receptor modulators PFIZER INC. (US) 2013-08-13 US disclosed
WO-2012107850-A1 GLUCAGON RECEPTOR MODULATOR PFIZER INC. (US) 2012-08-16 WO disclosed
US-20120202834-A1 GLUCAGON RECEPTOR MODULATORS PFIZER INC. (US) 2012-08-09 US disclosed
US-20120202834-A1 GLUCAGON RECEPTOR MODULATORS PFIZER INC. (US) 2012-08-09 US disclosed
US-20120202834-A1 GLUCAGON RECEPTOR MODULATORS PFIZER INC. (US) 2012-08-09 US disclosed
US-20120165343-A1 Glucagon Receptor Modulators PFIZER INC. (US) 2012-06-28 US disclosed
WO-2012085745-A1 GLUCAGON RECEPTOR MODULATORS PFIZER INC. (US) 2012-06-28 WO disclosed
US-20120165343-A1 Glucagon Receptor Modulators PFIZER INC. (US) 2012-06-28 US disclosed
WO-2012085745-A1 GLUCAGON RECEPTOR MODULATORS PFIZER INC. (US) 2012-06-28 WO disclosed
US-20120165343-A1 Glucagon Receptor Modulators PFIZER INC. (US) 2012-06-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150266859-A1 GLUCAGON RECEPTOR MODULATORS GLP1R, GCGR, GPR119 SMN1; SMN2 3570/4885MAPT 4254/4885PRSS1 1353/4885
US-20120165343-A1 Glucagon Receptor Modulators GLP1R, GCGR, GPR119 SMN1; SMN2 3570/4885MAPT 4254/4885PRSS1 1353/4885
US-20160362392-A1 GLUCAGON RECEPTOR MODULATORS GLP1R, GCGR, GPR119 SMN1; SMN2 3570/4885MAPT 4254/4885PRSS1 1353/4885
US-20150266861-A1 Glucagon Receptor Modulators GLP1R, GCGR, GPR119 SMN1; SMN2 3570/4885MAPT 4254/4885PRSS1 1353/4885
US-20120202834-A1 GLUCAGON RECEPTOR MODULATORS GLP1R, GCGR, GPR119 SMN1; SMN2 3570/4885MAPT 4254/4885PRSS1 1353/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.